JENLOGA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Jenloga, and what generic alternatives are available?
Jenloga is a drug marketed by Concordia Pharms Inc and is included in one NDA.
The generic ingredient in JENLOGA is clonidine hydrochloride. There are twenty-two drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the clonidine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Jenloga
A generic version of JENLOGA was approved as clonidine hydrochloride by ACTAVIS ELIZABETH on December 16th, 1986.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for JENLOGA?
- What are the global sales for JENLOGA?
- What is Average Wholesale Price for JENLOGA?
Summary for JENLOGA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 135 |
| Patent Applications: | 1,871 |
| DailyMed Link: | JENLOGA at DailyMed |
US Patents and Regulatory Information for JENLOGA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Concordia Pharms Inc | JENLOGA | clonidine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 022331-001 | Sep 30, 2009 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Concordia Pharms Inc | JENLOGA | clonidine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 022331-002 | May 25, 2010 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for JENLOGA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Concordia Pharms Inc | JENLOGA | clonidine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 022331-001 | Sep 30, 2009 | ⤷ Sign Up | ⤷ Sign Up |
| Concordia Pharms Inc | JENLOGA | clonidine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 022331-002 | May 25, 2010 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for JENLOGA
See the table below for patents covering JENLOGA around the world.
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
